Adenosine receptors and Alzheimer's disease

Adenosine: A Key Link between Metabolism and Brain Activity

Volumn , Issue , 2013, Pages 385-407

  Blum, David ^a,b,c   Sandau, Ursula ^d   Laurent, Cyril ^a,b   Batalha, Vânia ^e   Leboucher, Antoine ^a,b   Hamdane, Malika ^a,b,c   Pasquier, Florence ^c   Boison, Detlev ^d   Buée, Luc ^a,b,c   Lopes, Luísa V ^e  

^a INSERM   (France)

^b UNIV LILLE   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d LEGACY RESEARCH   (United States)

^e Instituto de Medicina Molecular   (Portugal)

Author keywords

Amyloid plaque; Brain derived neurotrophic factor; Caffeine; Inflammation; Neurofibrillary tangle; Tau protein

Indexed keywords

EID: 84902092562     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-3903-5_19     Document Type: Chapter

References (163)

1. Agostinho PM, Matos M, Augusto E, Rodrigues A, Cunha RA (2011) Amyloid-beta inhibits the astrocytic glutamate uptake through a mechanism involving adenosine A2A receptor activation. AD/PD meeting, 2011, Barcelona
2. Amatniek JC, Hauser WA, DelCastillo-Castaneda C, Jacobs DM, Marder K, Bell K, Albert M, Brandt J, Stern Y (2006) Incidence and predictors of seizures in patients with Alzheimer's disease. Epilepsia 47:867-872
3. Amieva H, Jacqmin-Gadda H, Orgogozo JM, Le Carret N, Helmer C, Letenneur L, Barberger-Gateau P, Fabrigoule C, Dartigues JF (2005) The 9 year cognitive decline before dementia of the Alzheimer type: A prospective population-based study. Brain 128:1093-1101
4. Angulo E, Casado V, Mallol J, Canela EI, Vinals F, Ferrer I, Lluis C, Franco R (2003) A1 adenosine receptors accumulate in neurodegenerative structures in Alzheimer disease and mediate both amyloid precursor protein processing and tau phosphorylation and translocation. Brain Pathol 13:440-451
5. Arendash GW, Schleif W, Rezai-Zadeh K, Jackson EK, Zacharia LC, Cracchiolo JR, Shippy D, Tan J (2006) Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain beta-amyloid production. Neuroscience 142:941-952
6. Arendash GW, Mori T, Cao C, Mamcarz M, Runfeldt M, Dickson A, Rezai-Zadeh K, Tane J, Citron BA, Lin X et al (2009) Caffeine reverses cognitive impairment and decreases brain amyloid-beta levels in aged Alzheimer's disease mice. J Alzheimers Dis 17:661-680
7. Assaife-Lopes N, Sousa VC, Pereira DB, Ribeiro JA, Chao MV, Sebastiao AM (2010) Activation of adenosine A2A receptors induces TrkB translocation and increases BDNF-mediated phospho-TrkB localization in lipid rafts: implications for neuromodulation. J Neurosci 30:8468-8480
8. Attems J, Jellinger KA (2006) Hippocampal sclerosis in Alzheimer disease and other dementias. Neurology 66:775
9. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E (2011) Alzheimer's disease. Lancet 377:1019-1031
10. Beach TG, Sue L, Scott S, Layne K, Newell A, Walker D, Baker M, Sahara N, Yen SH, Hutton M et al (2003) Hippocampal sclerosis dementia with tauopathy. Brain Pathol 13:263-278
11. Belarbi K, Burnouf S, Fernandez-Gomez FJ, Laurent C, Lestavel S, Figeac M, Sultan A, Troquier L, Leboucher A, Caillierez R et al (2011) Bene fi cial effects of exercise in a transgenic mouse model of Alzheimer's disease-like Tau pathology. Neurobiol Dis 43:486-494
12. Bellucci A, Westwood AJ, Ingram E, Casamenti F, Goedert M, Spillantini MG (2004) Induction of in fl ammatory mediators and microglial activation in mice transgenic for mutant human P301S tau protein. Am J Pathol 165:1643-1652
13. Bhaskar K, Konerth M, Kokiko-Cochran ON, Cardona A, Ransohoff RM, Lamb BT (2010) Regulation of tau pathology by the microglial fractalkine receptor. Neuron 68:19-31
14. Blum D, Burnouf S, Martire A, Belarbi K, Laurent C, Muhr-Tailleux A, Van der Jeugd A, Leboucher A, Fernandez-gomez F, Troquier L et al (2011) Impairment of BDNF-mediated hippocampal synaptic facilitation in a transgenic model of Alzheimer's disease-like Tau pathology. Society for neuroscience meeting, San Diego, 2010
15. Boison D (2008) The adenosine kinase hypothesis of epileptogenesis. Prog Neurobiol 84:249-262
16. Boison D (2011) Modulators of nucleoside metabolism in the therapy of brain diseases. Curr Top Med Chem 11:1068-1086
17. Brambilla R, Cottini L, Fumagalli M, Ceruti S, Abbracchio MP (2003) Blockade of A2A adenosine receptors prevents basic fi broblast growth factor-induced reactive astrogliosis in rat striatal primary astrocytes. Glia 43:190-194
18. Brodie C, Blumberg PM, Jacobson KA (1998) Activation of the A2A adenosine receptor inhibits nitric oxide production in glial cells. FEBS Lett 429:139-142
19. Brown SJ, James S, Reddington M, Richardson PJ (1990) Both A1 and A2a purine receptors regulate striatal acetylcholine release. J Neurochem 55:31-38
20. Bruns RF, Lu GH, Pugsley TA (1986) Characterization of the A2 adenosine receptor labeled by [3H]NECA in rat striatal membranes. Mol Pharmacol 29:331-346
21. Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR (2000) Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 33:95-130
22. Cagnin A, Brooks DJ, Kennedy AM, Gunn RN, Myers R, Turkheimer FE, Jones T, Banati RB (2001) In-vivo measurement of activated microglia in dementia. Lancet 358:461-467
23. Canas PM, Porciuncula LO, Cunha GM, Silva CG, Machado NJ, Oliveira JM, Oliveira CR, Cunha RA (2009) Adenosine A2A receptor blockade prevents synaptotoxicity and memory dysfunction caused by beta-amyloid peptides via p38 mitogen-activated protein kinase pathway. J Neurosci 29:14741-14751
24. Checler F (1995) Processing of the beta-amyloid precursor protein and its regulation in Alzheimer's disease. J Neurochem 65:1431-1444
25. Cognato GP, Agostinho PM, Hockemeyer J, Muller CE, Souza DO, Cunha RA (2010) Caffeine and an adenosine A(2A) receptor antagonist prevent memory impairment and synaptotoxicity in adult rats triggered by a convulsive episode in early life. J Neurochem 112:453-462
26. Costa MS, Botton PH, Mioranzza S, Souza DO, Porciuncula LO (2008) Caffeine prevents ageassociated recognition memory decline and changes brain-derived neurotrophic factor and tirosine kinase receptor (TrkB) content in mice. Neuroscience 153:1071-1078
27. Costenla AR, Cunha RA, de Mendonca A (2010) Caffeine, adenosine receptors, and synaptic plasticity. J Alzheimers Dis 20(Suppl 1):S25-S34
28. Cunha RA (2008) Caffeine, adenosine receptors, memory and Alzheimer disease. Med Clin (Barc) 131:790-795
29. Cunha RA, Johansson B, van der Ploeg I, Sebastiao AM, Ribeiro JA, Fredholm BB (1994) Evidence for functionally important adenosine A2a receptors in the rat hippocampus. Brain Res 649:208-216
30. Cunha RA, Constantino MC, Sebastiao AM, Ribeiro JA (1995) Modi fi cation of A1 and A2a adenosine receptor binding in aged striatum, hippocampus and cortex of the rat. Neuroreport 6:1583-1588
31. Cunha RA, Almeida T, Ribeiro JA (2001) Parallel modi fi cation of adenosine extracellular metabolism and modulatory action in the hippocampus of aged rats. J Neurochem 76:372-382
32. Cunha GM, Canas PM, Oliveira CR, Cunha RA (2006) Increased density and synapto-protective effect of adenosine A2A receptors upon sub-chronic restraint stress. Neuroscience 141:1775-1781
33. Cunha GM, Canas PM, Melo CS, Hockemeyer J, Muller CE, Oliveira CR, Cunha RA (2008) Adenosine A2A receptor blockade prevents memory dysfunction caused by beta-amyloid peptides but not by scopolamine or MK-801. Exp Neurol 210:776-781
34. Cunha C, Brambilla R, Thomas KL (2010) A simple role for BDNF in learning and memory? Front Mol Neurosci 3:1
35. Currais A, Kato K, Canuet L, Ishii R, Tanaka T, Takeda M, Soriano S (2011) Caffeine modulates tau phosphorylation and affects Akt signaling in postmitotic neurons. J Mol Neurosci 43:326-332
36. Dai SS, Li W, An JH, Wang H, Yang N, Chen XY, Zhao Y, Li P, Liu P, Chen JF et al (2010a) Adenosine A2A receptors in both bone marrow cells and non-bone marrow cells contribute to traumatic brain injury. J Neurochem 113:1536-1544
37. Dai SS, Zhou YG, Li W, An JH, Li P, Yang N, Chen XY, Xiong RP, Liu P, Zhao Y et al (2010b) Local glutamate level dictates adenosine A2A receptor regulation of neuroin fl ammation and traumatic brain injury. J Neurosci 30:5802-5810
38. Dall'Igna OP, Porciuncula LO, Souza DO, Cunha RA, Lara DR (2003) Neuroprotection by caffeine and adenosine A2A receptor blockade of beta-amyloid neurotoxicity. Br J Pharmacol 138:1207-1209
39. Dall'Igna OP, Fett P, Gomes MW, Souza DO, Cunha RA, Lara DR (2007) Caffeine and adenosine A(2a) receptor antagonists prevent beta-amyloid (25-35)-induced cognitive de fi cits in mice. Exp Neurol 203:241-245
40. de Mendonca A, Cunha RA (2010) Therapeutic opportunities for caffeine in Alzheimer's disease and other neurodegenerative disorders. J Alzheimers Dis 20(Suppl 1):S1-S2
41. de Mendonca A, Ribeiro JA (1994) Endogenous adenosine modulates long-term potentiation in the hippocampus. Neuroscience 62:385-390
42. De Strooper B (2010) Proteases and proteolysis in Alzheimer disease: A multifactorial view on the disease process. Physiol Rev 90:465-494
43. De Strooper B, Vassar R, Golde T (2010) The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol 6:99-107
44. Del Vecchio RA, Gold LH, Novick SJ, Wong G, Hyde LA (2004) Increased seizure threshold and severity in young transgenic CRND8 mice. Neurosci Lett 367:164-167
45. Dias RB, Ribeiro JA, Sebastiao AM (2010) Enhancement of AMPA currents and GluR1 membrane expression through PKA-coupled adenosine A(2A) receptors. Hippocampus 22:276-291
46. Diogenes MJ, Fernandes CC, Sebastiao AM, Ribeiro JA (2004) Activation of adenosine A2A receptor facilitates brain-derived neurotrophic factor modulation of synaptic transmission in hippocampal slices. J Neurosci 24:2905-2913
47. Diogenes MJ, Costenla AR, Lopes LV, Jeronimo-Santos A, Sousa VC, Fontinha BM, Ribeiro JA, Sebastiao AM (2011) Enhancement of LTP in aged rats is dependent on endogenous BDNF. Neuropsychopharmacology 36:1823-1836
48. Dostal V, Roberts CM, Link CD (2010) Genetic mechanisms of coffee extract protection in a Caenorhabditis elegans model of beta-amyloid peptide toxicity. Genetics 186:857-866
49. Duyckaerts C, Bennecib M, Grignon Y, Uchihara T, He Y, Piette F, Hauw JJ (1997) Modeling the relation between neuro fi brillary tangles and intellectual status. Neurobiol Aging 18:267-273
50. El Khoury J, Toft M, Hickman SE, Means TK, Terada K, Geula C, Luster AD (2007) Ccr2 de fi ciency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med 13:432-438
51. Eskelinen MH, Kivipelto M (2010) Caffeine as a protective factor in dementia and Alzheimer's disease. J Alzheimers Dis 20(Suppl 1):S167-S174
52. Eskelinen MH, Ngandu T, Tuomilehto J, Soininen H, Kivipelto M (2009) Midlife coffee and tea drinking and the risk of late-life dementia: A population-based CAIDE study. J Alzheimers Dis 16:85-91
53. Espana J, Valero J, Minano-Molina AJ, Masgrau R, Martin E, Guardia-Laguarta C, Lleo A, Gimenez-Llort L, Rodriguez-Alvarez J, Saura CA (2010) beta-Amyloid disrupts activitydependent gene transcription required for memory through the CREB coactivator CRTC1. J Neurosci 30:9402-9410
54. Fang F, Lue LF, Yan S, Xu H, Luddy JS, Chen D, Walker DG, Stern DM, Schmidt AM, Chen JX et al (2010) RAGE-dependent signaling in microglia contributes to neuroin fl ammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease. FASEB J 24:1043-1055
55. Fiebich BL, Biber K, Lieb K, van Calker D, Berger M, Bauer J, Gebicke-Haerter PJ (1996) Cyclooxygenase-2 expression in rat microglia is induced by adenosine A2a-receptors. Glia 18:152-160
56. Fisone G, Borgkvist A, Usiello A (2004) Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci 61:857-872
57. Fontinha BM, Diogenes MJ, Ribeiro JA, Sebastiao AM (2008) Enhancement of long-term potentiation by brain-derived neurotrophic factor requires adenosine A2A receptor activation by endogenous adenosine. Neuropharmacology 54:924-933
58. Fredholm BB, Battig K, Holmen J, Nehlig A, Zvartau EE (1999) Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 51:83-133
59. Fredholm BB, Chen JF, Cunha RA, Svenningsson P, Vaugeois JM (2005) Adenosine and brain function. Int Rev Neurobiol 63:191-270
60. Georgiev V, Johansson B, Fredholm BB (1993) Long-term caffeine treatment leads to a decreased susceptibility to NMDA-induced clonic seizures in mice without changes in adenosine A1 receptor number. Brain Res 612:271-277
61. Gimenez-Llort L, Schiffmann SN, Shmidt T, Canela L, Camon L, Wassholm M, Canals M, Terasmaa A, Fernandez-Teruel A, Tobena A et al (2007) Working memory de fi cits in transgenic rats overexpressing human adenosine A2A receptors in the brain. Neurobiol Learn Mem 87:42-56
62. Gold PE (2003) Acetylcholine modulation of neural systems involved in learning and memory. Neurobiol Learn Mem 80:194-210
63. Gomes CV, Kaster MP, Tome AR, Agostinho PM, Cunha RA (2011) Adenosine receptors and brain diseases: neuroprotection and neurodegeneration. Biochim Biophys Acta 1808:1380-1399
64. Gorlovoy P, Larionov S, Pham TT, Neumann H (2009) Accumulation of tau induced in neurites by microglial proin fl ammatory mediators. FASEB J 23:2502-2513
65. Grathwohl SA, Kalin RE, Bolmont T, Prokop S, Winkelmann G, Kaeser SA, Odenthal J, Radde R, Eldh T, Gandy S et al (2009) Formation and maintenance of Alzheimer's disease beta-amyloid plaques in the absence of microglia. Nat Neurosci 12:1361-1363
66. Grober E, Dickson D, Sliwinski MJ, Buschke H, Katz M, Crystal H, Lipton RB (1999) Memory and mental status correlates of modi fi ed Braak staging. Neurobiol Aging 20:573-579
67. Guerreiro S, Toulorge D, Hirsch E, Marien M, Sokoloff P, Michel PP (2008) Paraxanthine, the primary metabolite of caffeine, provides protection against dopaminergic cell death via stimulation of ryanodine receptor channels. Mol Pharmacol 74:980-989
68. Haskell CF, Kennedy DO, Wesnes KA, Scholey AB (2005) Cognitive and mood improvements of caffeine in habitual consumers and habitual non-consumers of caffeine. Psychopharmacology (Berl) 179:813-825
69. Hasko G, Pacher P, Vizi ES, Illes P (2005) Adenosine receptor signaling in the brain immune system. Trends Pharmacol Sci 26:511-516
70. Heneka MT, O'Banion MK (2007) In fl ammatory processes in Alzheimer's disease. J Neuroimmunol 184:69-91
71. Herber DL, Roth LM, Wilson D, Wilson N, Mason JE, Morgan D, Gordon MN (2004) Timedependent reduction in Abeta levels after intracranial LPS administration in APP transgenic mice. Exp Neurol 190:245-253
72. Hindley S, Herman MA, Rathbone MP (1994) Stimulation of reactive astrogliosis in vivo by extracellular adenosine diphosphate or an adenosine A2 receptor agonist. J Neurosci Res 38:399-406
73. Holmes C, Cunningham C, Zotova E, Woolford J, Dean C, Kerr S, Culliford D, Perry VH (2009) Systemic in fl ammation and disease progression in Alzheimer disease. Neurology 73:768-774
74. Hsia AY, Masliah E, McConlogue L, Yu GQ, Tatsuno G, Hu K, Kholodenko D, Malenka RC, Nicoll RA, Mucke L (1999) Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci USA 96:3228-3233
75. Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, Wol fi ng H, Chieng BC, Christie MJ, Napier IA et al (2010) Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 142:387-397
76. Jacobson KA, von Lubitz DK, Daly JW, Fredholm BB (1996) Adenosine receptor ligands: differences with acute versus chronic treatment. Trends Pharmacol Sci 17:108-113
77. Jin S, Fredholm BB (1997) Adenosine A2A receptor stimulation increases release of acetylcholine from rat hippocampus but not striatum, and does not affect catecholamine release. Naunyn Schmiedebergs Arch Pharmacol 355:48-56
78. Johansson B, Georgiev V, Lindstrom K, Fredholm BB (1997) A1 and A2A adenosine receptors and A1 mRNA in mouse brain: effect of long-term caffeine treatment. Brain Res 762:153-164
79. Johnson-Kozlow M, Kritz-Silverstein D, Barrett-Connor E, Morton D (2002) Coffee consumption and cognitive function among older adults. Am J Epidemiol 156:842-850
80. Kalda A, Yu L, Oztas E, Chen JF (2006) Novel neuroprotection by caffeine and adenosine A(2A) receptor antagonists in animal models of Parkinson's disease. J Neurol Sci 248:9-15
81. Kaplan GB, Greenblatt DJ, Leduc BW, Thompson ML, Shader RI (1989) Relationship of plasma and brain concentrations of caffeine and metabolites to benzodiazepine receptor binding and locomotor activity. J Pharmacol Exp Ther 248:1078-1083
82. Ke RH, Xiong J, Liu Y, Ye ZR (2009) Adenosine A2a receptor induced gliosis via Akt/NF-kappaB pathway in vitro. Neurosci Res 65:280-285
83. Kitazawa M, Oddo S, Yamasaki TR, Green KN, LaFerla FM (2005) Lipopolysaccharide-induced in fl ammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J Neurosci 25:8843-8853
84. Kurt MA, Davies DC, Kidd M (1999) beta-Amyloid immunoreactivity in astrocytes in Alzheimer's disease brain biopsies: An electron microscope study. Exp Neurol 158:221-228
85. La Rue A (2010) Healthy brain aging: role of cognitive reserve, cognitive stimulation, and cognitive exercises. Clin Geriatr Med 26:99-111
86. Lambert JC, Amouyel P (2011) Genetics of Alzheimer's disease: new evidences for an old hypothesis? Curr Opin Genet Dev 21:295-301
87. Lee FS, Chao MV (2001) Activation of Trk neurotrophin receptors in the absence of neurotrophins. Proc Natl Acad Sci USA 98:3555-3560
88. Lee DC, Rizer J, Selenica ML, Reid P, Kraft C, Johnson A, Blair L, Gordon MN, Dickey CA, Morgan D (2010a) LPS-induced in fl ammation exacerbates phospho-tau pathology in rTg4510 mice. J Neuroin fl ammation 7:56
89. Lee S, Varvel NH, Konerth ME, Xu G, Cardona AE, Ransohoff RM, Lamb BT (2010b) CX3CR1 de fi ciency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models. Am J Pathol 177:2549-2562
90. Li Y, Liu L, Barger SW, Grif fi n WS (2003) Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. J Neurosci 23:1605-1611
91. Li W, Dai S, An J, Li X, Chen X, Xiong R, Liu P, Wang H, Zhao Y, Zhu M, Liu X, Zhu P, Chen JF, Zhou Y (2008) Chronic but not acute treatment with cafeine attenuates traumatic brain injury in the mouse cortical impact model. Neuroscience 151:1198-1207
92. Linden J (2001) Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection. Annu Rev Pharmacol Toxicol 41:775-787
93. Lindsay J, Laurin D, Verreault R, Hebert R, Helliwell B, Hill GB, McDowell I (2002) Risk factors for Alzheimer's disease: A prospective analysis from the Canadian Study of Health and Aging. Am J Epidemiol 156:445-453
94. Lopes LV, Cunha RA, Ribeiro JA (1999) Cross talk between A(1) and A(2A) adenosine receptors in the hippocampus and cortex of young adult and old rats. J Neurophysiol 82:3196-3203
95. Lopes LV, Sebastiao AM, Ribeiro JA (2011) Adenosine and related drugs in brain diseases: present and future in clinical trials. Curr Top Med Chem 11:1087-1101
96. Lorist MM, Tops M (2003) Caffeine, fatigue, and cognition. Brain Cogn 53:82-94
97. Maia L, de Mendonca A (2002) Does caffeine intake protect from Alzheimer's disease? Eur J Neurol 9:377-382
98. Marques S, Batalha VL, Lopes LV, Outeiro TF (2011) Modulating Alzheimer's disease through caffeine: A putative link to epigenetics. J Alzheimers Dis 24:161-171
99. Menendez M (2005) Down syndrome, Alzheimer's disease and seizures. Brain Dev 27:246-252
100. Minkeviciene R, Rheims S, Dobszay MB, Zilberter M, Hartikainen J, Fulop L, Penke B, Zilberter Y, Harkany T, Pitkanen A et al (2009) Amyloid beta-induced neuronal hyperexcitability triggers progressive epilepsy. J Neurosci 29:3453-3462
101. Moreira PI, Santos MS, Oliveira CR, Shenk JC, Nunomura A, Smith MA, Zhu X, Perry G (2008) Alzheimer disease and the role of free radicals in the pathogenesis of the disease. CNS Neurol Disord Drug Targets 7:3-10
102. Morelli M, Di Paolo T, Wardas J, Calon F, Xiao D, Schwarzschild MA (2007) Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications. Prog Neurobiol 83:293-309
103. Morelli M, Carta AR, Jenner P (2009) Adenosine A2A receptors and Parkinson's disease. Handb Exp Pharmacol 589-615
104. Muller CE, Jacobson KA (2011) Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Acta 1808:1290-1308
105. Naert G, Rivest S (2011) CC chemokine receptor 2 de fi ciency aggravates cognitive impairments and amyloid pathology in a transgenic mouse model of Alzheimer's disease. J Neurosci 31:6208-6220
106. Nagele RG, Wegiel J, Venkataraman V, Imaki H, Wang KC (2004) Contribution of glial cells to the development of amyloid plaques in Alzheimer's disease. Neurobiol Aging 25:663-674
107. Nishizaki T (2004) ATP-and adenosine-mediated signaling in the central nervous system: Adenosine stimulates glutamate release from astrocytes via A2a adenosine receptors. J Pharmacol Sci 94:100-102
108. Nunomura A, Perry G, Pappolla MA, Friedland RP, Hirai K, Chiba S, Smith MA (2000) Neuronal oxidative stress precedes amyloid-beta deposition in Down syndrome. J Neuropathol Exp Neurol 59:1011-1017
109. Nygaard TG, Duvoisin RC, Manocha M, Chokroverty S (1989) Seizures in progressive supranuclear palsy. Neurology 39:138-140
110. Orr AG, Orr AL, Li XJ, Gross RE, Traynelis SF (2009) Adenosine A(2A) receptor mediates microglial process retraction. Nat Neurosci 12:872-878
111. Palop JJ, Mucke L (2009) Epilepsy and cognitive impairments in Alzheimer disease. Arch Neurol 66:435-440
112. Perez JL, Carrero I, Gonzalo P, Arevalo-Serrano J, Sanz-Anquela JM, Ortega J, Rodriguez M, Gonzalo-Ruiz A (2010) Soluble oligomeric forms of beta-amyloid (Abeta) peptide stimulate Abeta production via astrogliosis in the rat brain. Exp Neurol 223:410-421
113. Pinna A (2009) Novel investigational adenosine A2A receptor antagonists for Parkinson's disease. Expert Opin Investig Drugs 18:1619-1631
114. Polydoro M, Acker CM, Duff K, Castillo PE, Davies P (2009) Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology. J Neurosci 29:10741-10749
115. Prasanthi JR, Dasari B, Marwarha G, Larson T, Chen X, Geiger JD, Ghribi O (2010) Caffeine protects against oxidative stress and Alzheimer's disease-like pathology in rabbit hippocampus induced by cholesterol-enriched diet. Free Radic Biol Med 49:1212-1220
116. Rahman A (2009) The role of adenosine in Alzheimer's disease. Curr Neuropharmacol 7:207-216
117. Rebola N, Sebastiao AM, de Mendonca A, Oliveira CR, Ribeiro JA, Cunha RA (2003) Enhanced adenosine A2A receptor facilitation of synaptic transmission in the hippocampus of aged rats. J Neurophysiol 90:1295-1303
118. Rebola N, Rodrigues RJ, Lopes LV, Richardson PJ, Oliveira CR, Cunha RA (2005) Adenosine A1 and A2A receptors are co-expressed in pyramidal neurons and co-localized in glutamatergic nerve terminals of the rat hippocampus. Neuroscience 133:79-83
119. Rebola N, Lujan R, Cunha RA, Mulle C (2008) Adenosine A2A receptors are essential for long-term potentiation of NMDA-EPSCs at hippocampal mossy fi ber synapses. Neuron 57:121-134
120. Rebola N, Simoes AP, Canas PM, Tome AR, Andrade GM, Barry CE, Agostinho PM, Lynch MA, Cunha RA (2011) Adenosine A2A receptors control neuroin fl ammation and consequent hippocampal neuronal dysfunction. J Neurochem 117:100-111
121. Ribeiro JA, Sebastiao AM (2010) Modulation and metamodulation of synapses by adenosine. Acta Physiol (Oxf) 199:161-169
122. Riksen NP, Rongen GA, Smits P (2009) Acute and long-term cardiovascular effects of coffee: implications for coronary heart disease. Pharmacol Ther 121:185-191
123. Ritchie K, Artero S, Touchon J (2001) Classi fi cation criteria for mild cognitive impairment: A population-based validation study. Neurology 56:37-42
124. Ritchie K, Carriere I, de Mendonca A, Portet F, Dartigues JF, Rouaud O, Barberger-Gateau P, Ancelin ML (2007) The neuroprotective effects of caffeine: A prospective population study (the Three City Study). Neurology 69:536-545
125. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu GQ, Mucke L (2007) Reducing endogenous tau ameliorates amyloid beta-induced de fi cits in an Alzheimer's disease mouse model. Science 316:750-754
126. Rodrigues RJ, Canas PM, Lopes LV, Oliveira CR, Cunha RA (2008) Modi fi cation of adenosine modulation of acetylcholine release in the hippocampus of aged rats. Neurobiol Aging 29:1597-1601
127. Sasaki A, Kawarabayashi T, Murakami T, Matsubara E, Ikeda M, Hagiwara H, Westaway D, George-Hyslop PS, Shoji M, Nakazato Y (2008) Microglial activation in brain lesions with tau deposits: comparison of human tauopathies and tau transgenic mice TgTauP301L. Brain Res 1214:159-168
128. Saura J, Angulo E, Ejarque A, Casado V, Tusell JM, Moratalla R, Chen JF, Schwarzschild MA, Lluis C, Franco R et al (2005) Adenosine A2A receptor stimulation potentiates nitric oxide release by activated microglia. J Neurochem 95:919-929
129. Sawyer DA, Julia HL, Turin AC (1982) Caffeine and human behavior: Arousal, anxiety, and performance effects. J Behav Med 5:415-439
130. Schindowski K, Bretteville A, Leroy K, Begard S, Brion JP, Hamdane M, Buee L (2006) Alzheimer's disease-like tau neuropathology leads to memory de fi cits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor de fi cits. Am J Pathol 169:599-616
131. Schwarzschild MA, Agnati L, Fuxe K, Chen JF, Morelli M (2006) Targeting adenosine A2A receptors in Parkinson's disease. Trends Neurosci 29:647-654
132. Sebastiao AM, Ribeiro JA (1992) Evidence for the presence of excitatory A2 adenosine receptors in the rat hippocampus. Neurosci Lett 138:41-44
133. Sebastiao AM, Ribeiro JA (2009) Tuning and fi ne-tuning of synapses with adenosine. Curr Neuropharmacol 7:180-194
134. Sergeant N, Bretteville A, Hamdane M, Caillet-Boudin ML, Grognet P, Bombois S, Blum D, Delacourte A, Pasquier F, Vanmechelen E et al (2008) Biochemistry of Tau in Alzheimer's disease and related neurological disorders. Expert Rev Proteomics 5:207-224
135. Sheng JG, Mrak RE, Grif fi n WS (1994) S100 beta protein expression in Alzheimer disease: potential role in the pathogenesis of neuritic plaques. J Neurosci Res 39:398-404
136. Simard AR, Soulet D, Gowing G, Julien JP, Rivest S (2006) Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron 49:489-502
137. Simola N, Morelli M, Pinna A (2008) Adenosine A2A receptor antagonists and Parkinson's disease: state of the art and future directions. Curr Pharm Des 14:1475-1489
138. Smit HJ, Rogers PJ (2000) Effects of low doses of caffeine on cognitive performance, mood and thirst in low and higher caffeine consumers. Psychopharmacology (Berl) 152:167-173
139. Stoppelkamp S, Bell HS, Palacios-Filardo J, Shewan DA, Riedel G, Platt B (2011) In vitro modelling of Alzheimer's disease: degeneration and cell death induced by viral delivery of amyloid and tau. Exp Neurol 229:226-237
140. Sultan A, Nesslany F, Violet M, Begard S, Loyens A, Talahari S, Mansuroglu Z, Marzin D, Sergeant N, Humez S et al (2011) Nuclear tau, a key player in neuronal DNA protection. J Biol Chem 286:4566-4575
141. Takahashi RN, Pamplona FA, Prediger RD (2008) Adenosine receptor antagonists for cognitive dysfunction: A review of animal studies. Front Biosci 13:2614-2632
142. Tebano MT, Martire A, Chiodi V, Ferrante A, Popoli P (2010) Role of adenosine A(2A) receptors in modulating synaptic functions and brain levels of BDNF: A possible key mechanism in the pathophysiology of Huntington's disease. Scienti fi cWorldJournal 10:1768-1782
143. Thomas RJ (1997) Seizures and epilepsy in the elderly. Arch Intern Med 157:605-617
144. Trinh K, Andrews L, Krause J, Hanak T, Lee D, Gelb M, Pallanck L (2010) Decaffeinated coffee and nicotine-free tobacco provide neuroprotection in Drosophila models of Parkinson's disease through an NRF2-dependent mechanism. J Neurosci 30:5525-5532
145. Van der Jeugd A, Ahmed T, Burnouf S, Belarbi K, Hamdame M, Grosjean ME, Humez S, Balschun D, Blum D, Buee L et al (2011) Hippocampal tauopathy in tau transgenic mice coincides with impaired hippocampus-dependent learning and memory, and attenuated late-phase long-term depression of synaptic transmission. Neurobiol Learn Mem 95:296-304
146. Van Eldik LJ, Grif fi n WS (1994) S100 beta expression in Alzheimer's disease: relation to neuropathology in brain regions. Biochim Biophys Acta 1223:398-403
147. van Gelder BM, Buijsse B, Tijhuis M, Kalmijn S, Giampaoli S, Nissinen A, Kromhout D (2007) Coffee consumption is inversely associated with cognitive decline in elderly European men: The FINE Study. Eur J Clin Nutr 61:226-232
148. Wang JH, Ma YY, van den Buuse M (2006) Improved spatial recognition memory in mice lacking adenosine A2A receptors. Exp Neurol 199:438-445
149. Wegiel J, Imaki H, Wang KC, Wronska A, Osuchowski M, Rubenstein R (2003) Origin and turnover of microglial cells in fi brillar plaques of APPsw transgenic mice. Acta Neuropathol 105:393-402
150. Wei CJ, Li W, Chen JF (2011) Normal and abnormal functions of adenosine receptors in the central nervous system revealed by genetic knockout studies. Biochim Biophys Acta 1808: 1358-1379
151. Westerman MA, Cooper-Blacketer D, Mariash A, Kotilinek L, Kawarabayashi T, Younkin LH, Carlson GA, Younkin SG, Ashe KH (2002) The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J Neurosci 22:1858-1867
152. Wharton SB, O'Callaghan JP, Savva GM, Nicoll JA, Matthews F, Simpson JE, Forster G, Shaw PJ, Brayne C, Ince PG (2009) Population variation in glial fi brillary acidic protein levels in brain ageing: relationship to Alzheimer-type pathology and dementia. Dement Geriatr Cogn Disord 27:465-473
153. Wiese S, Jablonka S, Holtmann B, Orel N, Rajagopal R, Chao MV, Sendtner M (2007) Adenosine receptor A2A-R contributes to motoneuron survival by transactivating the tyrosine kinase receptor TrkB. Proc Natl Acad Sci USA 104:17210-17215
154. Wisniewski HM, Wegiel J (1991) Spatial relationships between astrocytes and classical plaque components. Neurobiol Aging 12:593-600
155. Wittchen HU, Jacobi F (2005) Size and burden of mental disorders in Europea critical review and appraisal of 27 studies. Eur Neuropsychopharmacol 15:357-376
156. Wyss-Coray T (2006) In fl ammation in Alzheimer disease: driving force, bystander or bene fi cial response? Nat Med 12:1005-1015
157. Wyss-Coray T, Lin C, Yan F, Yu GQ, Rohde M, McConlogue L, Masliah E, Mucke L (2001) TGFbeta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. Nat Med 7:612-618
158. Xu K, Bastia E, Schwarzschild M (2005) Therapeutic potential of adenosine A(2A) receptor antagonists in Parkinson's disease. Pharmacol Ther 105:267-310
159. Yee BK, Singer P, Chen JF, Feldon J, Boison D (2007) Transgenic overexpression of adenosine kinase in brain leads to multiple learning impairments and altered sensitivity to psychomimetic drugs. Eur J Neurosci 26:3237-3252
160. Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, Maeda J, Suhara T, Trojanowski JQ, Lee VM (2007) Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53:337-351
161. Yu L, Shen HY, Coelho JE, Araujo IM, Huang QY, Day YJ, Rebola N, Canas PM, Rapp EK, Ferrara J et al (2008) Adenosine A2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms. Ann Neurol 63:338-346
162. Zhou SJ, Zhu ME, Shu D, Du XP, Song XH, Wang XT, Zheng RY, Cai XH, Chen JF, He JC (2009) Preferential enhancement of working memory in mice lacking adenosine A(2A) receptors. Brain Res 1303:74-83
163. Zilka N, Stozicka Z, Kovac A, Pilipcinec E, Bugos O, Novak M (2009) Human misfolded truncated tau protein promotes activation of microglia and leukocyte in fi ltration in the transgenic rat model of tauopathy. J Neuroimmunol 209:16-25